Neurology

The researchers noted that during high-risk pregnancies, special monitoring and care throughout the pregnancy is mandatory.

Amy R. Dunleavy, PharmD, highlights various drug therapies used for the acute treatment of migraine and provides recommendations for appropriate use.

A panel discussion regarding the underdiagnosis and burden of migraine attacks on patients and the rationale for educating the community about signs and symptoms.

A study comparing once-monthly injectable galcanezumab-gnlm with rimegepant has been planned to support the assessment of potential treatments to prevent migraines.

Popular among European royalty, the consumption of human brain emerged in the 17th century as a cure to ailments of the mind.

The FDA recently approved the amyloid beta-directed antibody indicated for the treatment of the progressive disease.

The results of the study are consistent with several large-scale epidemiological studies that show an association between Parkinson and inflammatory bowel diseases, such as ulcerative colitis and Crohn disease.

Individuals receiving aducanumab showed significant dose- and time-dependent reduction of amyloid beta plaque, whereas patients in the control arm had no reduction, according to the FDA.

Rimegepant is indicated for adult patients with episodic migraines.

Matthew Harms, a medical consultant and care center director at the MDA and associate professor of neurology at Columbia University Medical Center, to discuss new treatments and anticipated developments for ALS over the next year.

Erenumab-aooe (Aimovig, Amgen) is indicated for the preventive treatment of migraine in adults, making it the first approved preventive migraine treatment of its kind.

The historical and cultural foundations of the use of psychedelic drugs, the failure of the war on drugs in the United States, and multiple examples of other countries successfully legalizing psychedelics without societal problems developing as a result make a clear argument for the legalization of psychedelic medicine.

HSV-1 can spread to the fetal brain during pregnancy and cause lifelong neurological problems, such as cognitive dysfunction, learning disabilities, and dementia.

Although it is currently used off-label for many neuroinflammatory and neurodegenerative disorders, intravenous immunoglobulin is showing promise for a growing number of neurological diseases.

More than half of participants in the MDMA-assisted therapy arm no longer qualified for a post-traumatic stress disorder diagnosis after 3 sessions, compared to 32% in the control arm.

Although therapeutics and vaccines for COVID-19 have dominated the news in the last year, development of other drugs has continued.

Although transthyretin can play a negative role in patients with amyloidosis, it may have protective effects in patients with Alzheimer disease.

Women who had migraines before menopause had a 29% increased risk of developing high blood pressure after menopause.

People who used positive airway pressure therapy were less likely than others to receive a new diagnosis of dementia or mild cognitive impairment over the next 3 years.

Research is the first to link chronic sinus inflammation with a neurobiological change.

A new study published in Nature Communications used artificial intelligence (AI) to identify 3 new multiple sclerosis (MS) subtypes, which may help identify which individuals are more likely to have disease progression, according to the authors.

April is Parkinson’s Awareness Month, so what better time to refresh your understanding and promote awareness around Parkinson disease than now?

Nine in 10 patients with multiple sclerosis who received the medication did not have worsening of 3-month disability, and ponesimod showed a numerical benefit in delaying disability progression.

Additionally, the study revealed for the first time the physiological reason for the neutral protection is increased blood flow to the brain as a result of higher levels of progesterone.

The study compared step impairments across the cognitive spectrum, including people with subjective cognitive impairment, Parkinson disease, mild cognitive impairment, Alzheimer disease, Lewy body dementia, and frontotemporal dementia, as well as cognitively healthy controls.